MindBio Therapeutics Appoints Venture Liquidity Providers for Market-Making Services

MindBio Therapeutics Corp. has engaged Venture Liquidity Providers to facilitate market-making for its common shares, aiming to enhance trading liquidity and market stability.

SD Metrowire Staff
Business
MindBio Therapeutics Appoints Venture Liquidity Providers for Market-Making Services

MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company focused on AI-driven voice analytics for drug and alcohol intoxication detection, announced it has appointed Venture Liquidity Providers (VLP), subject to regulatory and final approvals, to provide market-making services aimed at maintaining an orderly trading market for its common shares.

The service will be conducted through W.D. Latimer Co. Ltd. in compliance with Canadian Securities Exchange policies, with MindBio agreeing to pay $5,000 per month over a 12-month term, which may be terminated at any time, while both parties operate at arm’s length and VLP holds no direct or indirect interest in the company or its securities. For more details, see the full press release at https://ibn.fm/4evlA.

MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.

The appointment of VLP is expected to provide liquidity and potentially reduce price volatility, which could benefit shareholders. The market-making services are designed to ensure a more orderly trading environment for MBQIF shares on the OTCQB market. This move signals MindBio's commitment to maintaining a healthy trading market as it continues to advance its AI voice analytics technology.

About MindBio Therapeutics Corp.: MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.

For the latest news and updates relating to MBQIF, visit the company’s newsroom at https://ibn.fm/MBQIF.

Blockchain Registration

QR Code for Blockchain Registration